Immunotherapy Proven Effective in Patients with Brain Metastases as Well

A new, comprehensive study found that, in patients with brain metastases, immunotherapy independently of other treatment methods increased overall survival by 7.5 months. The findings of this analysis may address the concern, "Could immunotherapy be ineffective in patients with brain metastases?"
Kidney cancer, non-small cell lung cancer, breast cancer, colorectal (large bowel) cancer and skin cancer were present in the 3112 patients included in the study, in which immunotherapy reduced the risk of death by 38%. The researchers found that this rate increased further with radiotherapy and that, when immunotherapy was used together with radiotherapy, the risk of death was reduced compared with patients receiving radiotherapy alone by 41%. According to this study, median overall survival in patients receiving radiotherapy together with immunotherapy was 10.4 months, whereas in patients treated with radiotherapy alone it was 10 months (P =.003).
Dr. Amin, a researcher in the study, summarizes the issue as follows: “What makes our study unique is the increased survival rate with immunotherapy in patients with brain metastases after surgery for the primary cancer site. This association has not previously been investigated. We believe that the increased overall survival rate in patients receiving radiotherapy for brain metastases together with immunotherapy stems from radiotherapy’s mechanism of action. When tumor cells are stimulated by radiotherapy, they are damaged, increasing the release of tumor-associated antigens. This is extremely important for our immune system to recognize tumor cells and mount a response against them; it is critical. Immunotherapy may strengthen the immune system’s response against tumor cells and increase treatment effectiveness. Surgery at the primary tumor site is also very important here. In this way, the area the immune system needs to target is reduced and a more effective response is generated. Before recent studies, immunotherapy methods were thought to be ineffective in brain metastases. The reason was the belief that the blood-brain barrier, which plays an important role in brain integrity and protection, would prevent access to the metastatic site and that treatment would not achieve the desired effect. However, preclinical and clinical studies show that monoclonal antibodies cross the blood-brain barrier and reach the target area. This is an excellent treatment option for patients with brain metastases.”
Summary
The study results offer hope for brain metastases, which pose a serious risk of death. After surgery for the primary tumor site, adding immunotherapy to radiotherapy in patients with brain metastases increases overall survival. These findings pave the way for further clinical studies, while immunotherapy in combination with chemotherapy and chemoradiotherapy opens an avenue for scientists to determine the effectiveness of these combinations.
Sources
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.